GlassScriptPhysician profile
Michelle E Aquino
NPI 1851354484
$1,741.41
in general payments reported to CMS, 2019-2025
16 companies · $505 in 2025
The $505 reported for 2025 was more than what 90% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $36.63 · 2021: $69.69 · 2022: $159 · 2023: $419 · 2024: $406 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $339.91 | 2022-2024 | Farxiga, Lokelma, Wainua |
| Abbvie INC. | $334.83 | 2022-2025 | Dalvance |
| Janssen Pharmaceuticals, INC | $200.08 | 2021-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.24 | 2024-2025 | Xifaxan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.45 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $111.63 | 2020-2024 | |
| Alexion Pharmaceuticals, INC. | $92.25 | 2019-2023 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $91.65 | 2019-2025 | Camzyos |
| Aimmune Therapeutics, INC. | $62.94 | 2023-2024 | |
| Pfizer INC. | $60.94 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $44.13 | 2024-2025 | Verquvo |
| Edwards Lifesciences Corporation | $25.94 | 2022 | |
| Ucb, INC. | $22.90 | 2019 | |
| Boston Scientific Corporation | $21.53 | 2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.89 | 2024 | Jardiance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $16.10 | 2024 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Aquino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.